BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin Pharmacother. 2014;15:1337-1349. [PMID: 24773464 DOI: 10.1517/14656566.2014.913571] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Mårdh O, Quinten C, Amato-Gauci AJ, Duffell E. Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA - descriptive analysis and estimation of 2015 baseline. Infect Dis (Lond) 2020;52:625-37. [PMID: 32644030 DOI: 10.1080/23744235.2020.1766104] [Reference Citation Analysis]
2 Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex (Engl Ed) 2018;83:275-324. [PMID: 29803325 DOI: 10.1016/j.rgmx.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
3 Dustin LB. Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 2017;18:826-43. [PMID: 26302811 DOI: 10.2174/1389450116666150825110532] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
4 Hamdy M, Kassim SK, Khairy E, Maher M, Mansour KA, Albreedy AM. Ghrelin gene polymorphism as a genetic biomarker for prediction of therapy induced clearance in Egyptian chronic HCV patients. Gene 2018;649:74-9. [PMID: 29374597 DOI: 10.1016/j.gene.2018.01.077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Zacharakis G, Alzahrani J. Reactivation of Hepatitis B Virus During Treatment of Hepatitis C Genotype 3 with Daclatasvir and Sofosbuvir in a Patient with Dual Infection of Hepatitis B and Hepatitis C Virus. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.12531] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zhao H, Wang Y, Shao Y, Liu J, Li J, Zong H, Xing M. Characterization of Whooper Swan ( Cygnus cygnus ) Interferon α: Prokaryotic Expression, Biological Activities, and Physicochemical Characteristics. Journal of Interferon & Cytokine Research 2018;38:20-8. [DOI: 10.1089/jir.2017.0089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Coppola N, Minichini C, Starace M, Sagnelli C, Sagnelli E. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals: HCV Mutations Versus DAAs. J Med Virol 2016;88:1659-71. [DOI: 10.1002/jmv.24527] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
8 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; l’International Network on Hepatitis among Substance Users (Réseau international sur l’hépatite chez les consommateurs de drogues). Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. Int J Drug Policy 2015:S0955-3959(15)00351-5. [PMID: 26847504 DOI: 10.1016/j.drugpo.2015.11.009] [Reference Citation Analysis]
9 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; im Namen vom International Network on Hepatitis care in Substance Users. Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden. Int J Drug Policy 2015:S0955-3959(15)00352-7. [PMID: 26749563 DOI: 10.1016/j.drugpo.2015.11.010] [Reference Citation Analysis]
10 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ. Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral. International Journal of Drug Policy 2015. [DOI: 10.1016/j.drugpo.2015.11.011] [Reference Citation Analysis]
11 Coppola N, Pisaturo M, Zampino R, Macera M, Sagnelli C, Sagnelli E. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World J Gastroenterol 2015; 21(38): 10749-10759 [PMID: 26478667 DOI: 10.3748/wjg.v21.i38.10749] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
12 Coppola N, Pisaturo M, Sagnelli C, Onorato L, Sagnelli E. Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases 2015; 3(9): 807-822 [PMID: 26380828 DOI: 10.12998/wjcc.v3.i9.807] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
13 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015;26:1028-38. [PMID: 26282715 DOI: 10.1016/j.drugpo.2015.07.005] [Cited by in Crossref: 127] [Cited by in F6Publishing: 123] [Article Influence: 18.1] [Reference Citation Analysis]
14 Coppola N, Martini S, Pisaturo M, Sagnelli C, Filippini P, Sagnelli E. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World J Virology 2015; 4(1): 1-12 [PMID: 25674512 DOI: 10.5501/wjv.v4.i1.1] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
15 Boccaccio V, Bruno S. Optimal management of patients with chronic hepatitis C and comorbidities. Liver Int 2015;35:35-43. [DOI: 10.1111/liv.12712] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
16 Méndez-sánchez N, Paraná R, Cheinquer H, Alves de Mattos A, Gadano A, Silva M, Pessôa MG, Gomes-ferraz ML, Soza A, Mendes-correa MC, Chávez-tapia NC, Dagher L, Padilla M, Hernandez N, Sánchez-avila JF, Contreras F, Moraes-coelho HS, Parise ER, Bessone F, Uribe M. Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. Annals of Hepatology 2014;13:S4-S66. [DOI: 10.1016/s1665-2681(19)30920-2] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Dustin LB, Cashman SB, Laidlaw SM. Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol. 2014;96:535-548. [PMID: 25015956 DOI: 10.1189/jlb.4ri0214-126r] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]